# US 10,119,139 B2 · Treatment for conditions associated with fibrosis and collagen deposition > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,119,139 B2 - Document ID: US10119139B2 - Status: Granted - Kind: B2 - Application number: 15/265,813 - Filed: 2016-09-14 - Published: 2017-03-16 - Granted: 2018-11-06 - Earliest claimed: 2015-09-14 - Assignees: Vanderbilt University; Yale University - Applicants: Vanderbilt University; Yale University - Inventors: David G. Harrison; Kim Ramil Montaniel; Kasey C. Vickers; Jing Wu; Jay D. Humphrey; Matthew R. Bersi - Web page: https://patentgrep.com/patent/US10119139B2 ## CPC - C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} - A61K 31/7088: Compounds having three or more nucleosides or nucleotides - A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - C12Q 1/6883: for diseases caused by alterations of genetic material - A61B 17/22: Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for - A61B 2017/22001: {Angioplasty, e.g. PCTA} - A61B 2017/22051: {with an inflatable part, e.g. balloon, for positioning, blocking, or immobilisation (A61B2017/22048, A61B2017/3486 take precedence)} - C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs - C12N 2310/3231: having an additional ring, e.g. LNA, ENA - C12Q 2600/158: Expression markers - C12Q 2600/178: miRNA, siRNA or ncRNA - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D) ## Abstract Methods, compositions, devices, and kits for treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition are provided. The method of treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition in a subject includes administering an effective amount a miRNA-762 inhibitor to the subject, wherein the subject is identified as having a risk of developing and/or a need for treatment of the condition associated with fibrosis and/or collagen deposition. The kit includes a vial containing an miRNA-762 inhibitor and a device for use in a surgery creating a risk of fibrosis and/or collagen deposition. The composition includes a pharmaceutical composition comprising a miRNA-762 inhibitor and a second agent selected from the group consisting of: an angiotensin-converting enzyme (ACE) inhibitors, an angiotensin receptor blocker (ARB), another antihypertensive agent, a steroid, and combinations thereof. ## Claims ### Claim 1 A treatment method for HTN-induced kidney damage, Ang II induced aortic fibrosis, or upregulation of matrix degrading matrix metalloproteinases (MMPs), comprising: administering an effective amount of a miRNA-762 inhibitor to a subject; wherein the subject is in need of treatment for HTN-induced kidney damage, Ang II induced aortic fibrosis, or upregulation of matrix degrading MMPs. ### Claim 2 (depends on 1) The method of claim 1, and further comprising determining the levels of miR-762 in a sample from the subject. ### Claim 3 (depends on 2) The method of claim 2, wherein the sample includes excess levels of miR-762 as compared to a control. ### Claim 4 (depends on 1) The method of claim 1, wherein the miRNA-762 inhibitor is an oligonucleotide of 8-49 nucleotides in length having a sequence targeted to miRNA-762, or a precursor thereof. ### Claim 5 (depends on 4) The method of claim 4, wherein the oligonucleotide is an antisense oligonucleotide that is at least partially complementary to the sequence of the target miRNA, or a precursor thereof. ### Claim 6 (depends on 5) The method of claim 5, wherein the antisense oligonucleotide is selected from the group consisting of a ribonucleotide, a deoxyribonucleotide, an anti-sense molecule, a siRNA molecule, a shRNA molecule, a miRNA sponge, a cDNA, an antagomir, a locked nucleic acid (LNA) oligonucleotide, a decoy oligonucleotide, a peptide nucleic acid (PNA), a morpholino oligonucleotide, or a combination thereof. ### Claim 7 (depends on 5) The method of claim 5, wherein the oligonucleotide consists of a locked nucleic acid (LNA) oligonucleotide. ### Claim 8 (depends on 7) The method of claim 7, wherein the oligonucleotide is selected from the group consisting of: (a) a nucleotide sequence comprising at least 16 contiguous nucleotides complementary to the sequence of SEQ ID NO: 1 and modifications excluding base substitutions thereof; (b) a nucleotide sequence comprising at least 16 contiguous nucleotides complementary to the sequence of SEQ ID NO. 2 and modifications excluding base substitutions thereof; and (c) a nucleotide sequence comprising at least 8 contiguous nucelotides complementary to the sequence of a fragment consisting of a subsequence of SEQ ID NO: 2 of at least 8 contiguous nucleotides thereof. ### Claim 9 (depends on 4) The method of claim 4, wherein the oligonucleotide is modified to include a 2′-deoxy-2′-fluoro-beta-D-arabinose backbone. ### Claim 10 (depends on 1) The method of claim 1, wherein the miRNA-762 inhibitor is associated with a carrier molecule selected from the group consisting of a nanoparticle, a liposome, and a lipoprotein. ### Claim 11 (depends on 1) The method of claim 1, wherein the subject does not have vascular calcification. ### Claim 12 (depends on 1) The method of claim 1, wherein the inhibitor is administered at a site of fibrosis, scarring, or keloid. ### Claim 13 (depends on 12) The method of claim 12, wherein the inhibitor is administered topically or by local injection. ### Claim 14 (depends on 1) The method of claim 1, wherein the inhibitor is associated with a device selected from the group consisting of a stent coated with the inhibitor and a bandage comprising the inhibitor. ### Claim 15 A method of upregulating matrix degrading matrix metalloproteinases (MMPs) in a subject having fibrosis, scarring, or keloid, comprising: administering an effective amount a miRNA-762 inhibitor to the subject. ### Claim 16 (depends on 15) The method of claim 15, wherein the miRNA-762 inhibitor is administered at a site of fibrosis, scarring, or keloid. ### Claim 17 A method of upregulating matrix degrading matrix metalloproteinases (MMPs) in a subject, comprising: administering an effective amount a miRNA-762 inhibitor to the subject; wherein the subject is identified as having or being at risk for developing perivascular fibrosis, fibrosis of a blood vessel, aortic stiffening/hypertension, vascular fibrosis, vascular disease, and vascular inflammation.